Gilead Sciences, Inc. Share Price & Technical Analysis
GILD · $134.4 (+2.96%)
Healthcare / Drug Manufacturers - General
$134.4
+2.96%
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
3% return in May, -1% avg return in past 3 year May month.
13% return in 2026, 13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 16% | 6% | -6% | -6% | 3% | – | – | – | – | – | – | – | 13% |
| 25 | 5% | 18% | -2% | -5% | 4% | 2% | 1% | 1% | -2% | 7% | 5% | -3% | 30% |
| 24 | -3% | -8% | 1% | -11% | -2% | 7% | 11% | 4% | 5% | 6% | 5% | 0% | 15% |
| 23 | -1% | -4% | 3% | -1% | -7% | -1% | 0% | 1% | -3% | 5% | -3% | 5% | -6% |
| 22 | -5% | -12% | -1% | 0% | 9% | -5% | -3% | 6% | -3% | 26% | 12% | -3% | 21% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Uptrend
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$170.01B
P/E ratio
18.66
52W high
$157.3
52W low
$104.5
Volume
59,73,641
Beta
0.33
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Gilead Sciences, Inc. share price today?
- Gilead Sciences, Inc. (GILD) last traded around $134.4 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GILD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GILD. Download the app for real-time alerts.
- How can I analyze Gilead Sciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.